Cas:106-49-0 p-toluidine manufacturer & supplier

We serve Chemical Name:p-toluidine CAS:106-49-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

p-toluidine

Chemical Name:p-toluidine
CAS.NO:106-49-0
Synonyms:4-aminotoluene;4-Aminotoluene,4-Methylaniline;p-methylaniline;EINECS 203-403-1;tolyamine;p-Toluidine;p-toluidyna;MFCD00007906;p-Toluidin;1-amino-4-methylbenzene;4-Toluidine;para-methylaniline;Tolylamine;4-methylbenzenamine
Molecular Formula:C7H9N
Molecular Weight:107.153
HS Code:2921430090

Physical and Chemical Properties:
Melting point:41-46 °C(lit.)
Boiling point:197.4±9.0 °C at 760 mmHg
Density:1.0±0.1 g/cm3
Index of Refraction:1.568
PSA:26.02000
Exact Mass:107.073502
LogP:1.40

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3451 6.1/PG 2
Packing Group:II


Contact us for information like 4-aminotoluene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-methylbenzenamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,p-toluidyna Use and application,p-Toluidin technical grade,usp/ep/jp grade.


Related News: Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs. p-toluidine manufacturer They have also voiced frustrations about patients from mainland China hiding their travel and medical history, potentially endangering other patients. p-toluidine supplier AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer. p-toluidine vendor Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. p-toluidine factory They have also voiced frustrations about patients from mainland China hiding their travel and medical history, potentially endangering other patients.